Canatu grants commercial production license to FINE SEMITECH for CNT pellicle manufacturing
Canatu has granted a commercial production license for its CNT100 SEMI reactor to Korean semiconductor firm FINE SEMITECH CORPORATION (FST). The license allows FST to mass-produce CNT pellicle membranes and operate the reactor independently. Canatu will receive a one-time license fee for the commercial rights.
The license fee is valued within the lower half of Canatu’s “Medium” range, between 1 million and 5 million euros. The company expects to record the revenue in the fourth quarter of 2025.
Canatu prepares for long-term revenue streams
The new license will create two additional income sources for Canatu. The company will supply proprietary consumables used in CNT production and receive royalties for each CNT pellicle sold by FST. However, these revenues will depend on FST’s manufacturing output and customer demand.
“This marks a significant milestone, bringing our customer closer to high-volume mass production of CNT pellicle membranes,” said Canatu CEO Juha Kokkonen. “It also validates the maturity of CNT pellicle technology and demonstrates market demand.”
Milestone in global nanotechnology expansion
The CNT100 SEMI reactor was shipped to FST in September 2024. By July 2025, both the reactor and its post-processing equipment passed the customer’s Site Acceptance Test (SAT). The new license follows the companies’ roadmap toward commercial deployment.
The collaboration reflects the growing role of carbon nanotube technology in semiconductor manufacturing. With the deal, Canatu and FST are positioning themselves to meet the rising demand for durable and efficient CNT pellicles used in EUV lithography.
